Anifrolumab and Dermatomyositis
Published: 4 April 2025| Version 1 | DOI: 10.17632/pydccyf54m.1
Contributors:
Anagha Srivatsa, , , , , Description
The purpose of this systematic review was to evaluate the potential of anifrolumab as a novel treatment for dermatomyositis. We searched the PubMed, Embase, and Cochrane libraries for articles related to anifrolumab and dermatomyositis. Of the 50 articles screened, six met the criteria for inclusion (Figure 1). The 2009 Oxford levels of evidence were used to evaluate the quality of all articles included (Mendeley supplementary table 1).
Files
Institutions
Wayne State University School of Medicine
Categories
Dermatology, Dermatomyositis